Haizheng Pharmaceutical announced that Zhejiang Haizheng Animal Health Products Co., Ltd., a holding subsidiary of the company, has received an approval document for telmisartan oral solution veterinary drug product approved by the Ministry of Agriculture and Rural Affairs. The approval number is valid from October 8, 2026 to October 7, 2031. The product is used to treat proteinuria caused by chronic kidney disease in cats. This approval will enrich the company's product structure and promote the strategic layout of the pet medicine sector. There is uncertainty about product launch and sales.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.